Imeik Technology Development Co.,Ltd. Share Price

Equities

300896

CNE100004868

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. 23:00:00 17/07/2024 BST 5-day change 1st Jan Change
171.2 CNY -0.12% Intraday chart for Imeik Technology Development Co.,Ltd. +6.77% -18.57%

Financials

Sales 2024 * 3.87B 532M 41.13B Sales 2025 * 5.12B 705M 54.47B Capitalization 51.5B 7.09B 548B
Net income 2024 * 2.45B 337M 26.05B Net income 2025 * 3.19B 439M 33.94B EV / Sales 2024 * 12.3 x
Net cash position 2024 * 3.97B 547M 42.22B Net cash position 2025 * 5.85B 805M 62.21B EV / Sales 2025 * 8.92 x
P/E ratio 2024 *
21.5 x
P/E ratio 2025 *
16.5 x
Employees 910
Yield 2024 *
1.88%
Yield 2025 *
2.35%
Free-Float 35%
More Fundamentals * Estimated data
Dynamic Chart
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Imeik Technology Development's Profit Rises 47% on Higher Revenue MT
Imeik Technology Development Co.,Ltd. Proposes Final Dividend for the Year 2023 CI
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Imeik Technology Development Co.,Ltd.'s Equity Buyback Plan announced on June 12, 2023. CI
Imeik Technology Development Co.,Ltd.'s Equity Buyback announced on June 12, 2023, has closed with 1,165,874 shares, representing 0.54% for CNY 399.69 million. CI
QL Biopharmaceutical announced that it has received CNY 200 million in funding from BlueRun Investment Consulting Co., Ltd., Imeik Technology Development Co.,Ltd., China-US Green Fund Management Co., Ltd., Shenzhen Jiayuan Capital Management Co., Ltd., Chengdu Science and Technology Innovation Investment Group Co., Ltd., Shanghai Jincheng Equity Investment Fund Management Co., Ltd. and other investors CI
Imeik Technology Wins Exclusive Rights to Distribute Jeisys’ Aesthetic Equipment in China MT
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tranche Update on Imeik Technology Development Co.,Ltd.'s Equity Buyback Plan announced on June 12, 2023. CI
Imeik Technology Development Co.,Ltd. Approves Cash Distribution for the First Half of 2023, Payable on 23 October 2023 CI
Imeik Technology Development Co.,Ltd. Proposes Distribution for the First Half of 2023 CI
Imeik Technology Development's Profit Jumps 65.7% in H1 MT
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tranche Update on Imeik Technology Development Co.,Ltd.'s Equity Buyback Plan announced on June 12, 2023. CI
More news
1 day-0.12%
1 week+6.77%
Current month-0.52%
1 month-8.03%
3 months-19.10%
6 months-22.32%
Current year-18.57%
More quotes
1 week
164.51
Extreme 164.51
174.50
1 month
154.10
Extreme 154.1
189.45
Current year
154.10
Extreme 154.1
255.71
1 year
154.10
Extreme 154.1
352.42
3 years
154.10
Extreme 154.1
580.71
5 years
123.41
Extreme 123.4127
603.17
10 years
123.41
Extreme 123.4127
603.17
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 31/12/09
Director of Finance/CFO 46 31/10/21
44 -
Members of the board TitleAgeSince
Chairman 68 16/11/22
Director/Board Member 59 11/07/21
Director/Board Member 57 16/11/22
More insiders
Date Price Change Volume
17/07/24 171.2 -0.12% 3 115 240
17/07/24 171.4 +3.13% 3,350,635
16/07/24 166.2 -0.25% 1,548,496
15/07/24 166.6 -1.52% 1,629,039
12/07/24 169.2 +0.12% 2,704,234

End-of-day quote Shenzhen S.E., July 17, 2024

More quotes
Imeik Technology Development Co Ltd is a China-based company mainly engaged in the research and development, production and sales of biomedical materials. The Company focuses on the development and transformation of biomedical materials, and is committed to the development of biomedicine such as recombinant proteins and peptides. The Company has realized the industrialization of injection-type sodium hyaluronate series products and polydioxanone facial implants, and has established a product technology transformation platform for biomedical materials such as medical chitosan and polylactic acid. The Company's self-developed products are mainly aimed at the repair of fold skin on the face and neck. The clinical applications of its products cover medical cosmetology, surgical repair, and treatment of metabolic diseases. The Company mainly conducts its businesses in the China market.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
171.2 CNY
Average target price
316.7 CNY
Spread / Average Target
+85.00%
Consensus
  1. Stock Market
  2. Equities
  3. 300896 Stock